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PSTATE-OF-THE-ART PAPER
C-Reactive Protein Gene Polymorphisms, C-Reactive
Protein Blood Levels, and Cardiovascular Disease Risk
Fadi G. Hage, MD, Alexander J. Szalai, PHD
Birmingham, Alabama
C-reactive protein (CRP), a blood marker of inflammation and a hallmark of the acute-phase response, has been
shown to be a powerful and specific predictor of cardiovascular event risk in populations of otherwise healthy
persons. Here we review what is known about CRP gene polymorphisms, discuss how these might affect the
epidemiology of CRP and our understanding of CRP’s contribution to cardiovascular disease, and examine their
potential clinical usefulness. Evidence shows that certain subtle variations in the CRP gene sequence, mostly
single nucleotide polymorphisms, predictably and strongly influence the blood level of CRP. Some of these varia-
tions are associated with clinical correlates of cardiovascular disease. If future studies can establish with cer-
tainty that CRP influences cardiovascular biology, then CRP gene profiling could have clinical utility. (J Am Coll
Cardiol 2007;50:1115–22) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.012“
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1-reactive protein (CRP) was discovered in 1930 by Tillet
nd Francis during their studies of patients with acute
neumonia (1). They found that when serum from febrile
atients was mixed with a cell-wall component of pneumo-
occi that they called “Fraction C,” a precipitate formed.
his property was subsequently found to be due to reactivity
f CRP, present at high levels in “acute-phase” sera, with a
olysaccharide in the pneumococcal cell wall (C-
olysaccharide). C-reactive protein was the first of many
cute-phase reactants subsequently discovered (2), but today
levation of CRP is still considered the hallmark of the
cute-phase response.
C-reactive protein is a member of the phylogentically
ncient and conserved pentraxin family of proteins. Human
RP (Fig. 1) consists of 5 noncovalently bound subunits of
06 amino acids, each arranged symmetrically around a
entral pore. The molecule has a ligand recognition face that
ontains a Ca2-dependent binding site, as well as an
ffector molecule binding face that is able to initiate fluid-
hase pathways of host defense (by activating the comple-
ent system) and cell-mediated pathways (by activating
omplement and by binding to the Fc receptors of immu-
oglobulin G) (3) (Fig. 1). The rise in blood CRP after
issue insult or injury is rapid and robust, with levels
ncreasing by as much as 1,000-fold above baseline within
4 h. This behavior makes blood CRP an ideal clinical
arker of a patient’s general health status, and it has thus
een used for decades (4). The recent introduction of
rom the Department of Medicine, University of Alabama at Birmingham, Birming-
am, Alabama.
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p
Mhigh-sensitivity CRP” assays, technologies that allow cli-
icians to detect the low levels of blood CRP in ostensibly
ealthy people, has resulted in accumulation of vast
mounts of data linking blood CRP to various kinds of
ardiovascular diseases (5). At the same time, new evidence
rom animal models indicates that CRP might actually have
pathogenic role in vascular disease (6–9).
It has long been recognized that environmental variables
nd patient behaviors and traits such as smoking, infections,
ge, gender, lipid levels, and blood pressure can contribute
o variation in baseline CRP level1 (10). Indeed, obesity is a
ajor determinant of CRP levels in humans, and elevated
evels of CRP predict the development of type 2 diabetes
ellitus and the metabolic syndrome (11,12). Elevated
RP levels in these conditions are related to insulin resis-
ance (13), and weight loss can reduce CRP levels (14).
ewer evidence indicates an additional and substantial
enetic component (10,15,16). The realization that CRP
enetic polymorphisms do exist and that certain of these
irectly and predictably influence steady-state blood CRP
evel could be of substantial clinical importance, because
enetic predisposition to high baseline CRP might account
or a significant proportion of people with a higher than
verage risk of heart disease (17). Herein we review the
vailable evidence showing that a variety of CRP gene
olymorphisms are statistically associated with blood CRP
evel, that certain of these are biologically functional in that
hey directly alter CRP blood levels, and that some CRP
ariants are linked to a risk of heart and blood-vessel disease.
Because of the highly skewed distribution of human CRP blood levels, the
opulation statistic most often reported in the epidemiologic literature is the median.
ean CRP levels and transformed CRP levels are also reported.
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CRP Gene Polymorphisms September 18, 2007:1115–22Localization and
Structure of the CRP Gene
On the basis of the amino acid
sequence of the protein, White-
head et al. (18) synthesized
CRP-specific oligonucleotides
and used these to screen a human
liver c-deoxyribonucleic acid li-
brary. The clone pCRP1 was
thus isolated, sequenced, and
used as a probe to localize the
uman CRP gene to chromosome 1. This launched the
ra of CRP genetics. C-reactive protein was subsequently
apped to the proximal long arm of chromosome 1 in the
q23.2 region (19,20) (Fig. 2). The CRP gene sequence
as simultaneously determined in 1985 by 2 different
roups (21,22), both reporting that it is composed of 1
ntron separating 2 exons (Fig. 2). The first exon encodes
signal peptide and the first 2 amino acids of the mature
rotein. This is followed by a 278-nucleotide-long intron
hat includes a GT repeat sequence. The second exon
ncodes the remaining 204 amino acids, followed by a
top codon. Goldman et al. (23) were the first to show
hat the GT stretch in the intron is polymorphic in
ength.
Once the CRP gene was identified and its sequence
eported, several groups investigated its proximal pro-
oter region and how this regulates messenger ribonu-
Figure 1 Blood CRP Circulates as a Pentamer
One face of the pentamer supports multipoint attachment to ligands and
ligand-decorated surfaces; the other face binds C1q and FcR. Only some of
the many C-reactive protein (CRP) ligands are listed. HDL  high-density
lipoprotein; oxLDL  oxidized low-density lipoprotein.
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CRP  C-reactive protein
IL  interleukin
SLE  systemic lupus
erythematosus
SNP  single nucleotide
polymorphismcleic acid production. Several reviews of that subject are
vailable (3,24,25). Fundamentally, regulation of CRP
xpression occurs mostly at the transcriptional level, with
nterleukin (IL)-6 being the major inducer and IL-1
cting synergistically to enhance the effect (26). Accord-
ngly, certain polymorphisms of the IL-1 (27,28) and
L-6 (29) genes associate with differences in blood CRP
evel. Both IL-1 and IL-6 polymorphisms have been linked
o myocardial infarctions and stroke (30,31) and to mortal-
ty after acute coronary syndromes (32). Studies using mice
xpressing human CRP from the human CRP promoter
ave shown that although IL-6 is necessary for the induc-
ion of the CRP gene, it is not by itself sufficient (33,34). In
umans, CRP blood levels are generally higher in females
han in males (35), whereas in mice, expression of the
uman CRP transgene exhibits the opposite pattern (33). It
s important to note that in vitro studies of regulation of
RP gene expression have focused solely on primary hepa-
ocytes, hepatocyte cell lines, or a variety of transfected cell
ines (3,24,25). With the recent realization that CRP can be
ocally produced by the vasculature (7,36), however, this
rea needs to be reinvestigated to determine whether the
ame regulatory mechanisms are operating in cells of non-
epatic origin.
In this review we will not discuss further IL-6, IL-1,
ender hormones, or any other of the multitude of trans-
cting factors and their genes that might themselves be
olymorphic and might participate in CRP gene regulation.
ather, we will focus on the CRP gene per se and
ystematically discuss its many polymorphic cis-acting ele-
ents. We will in turn examine evidence that the CRP gene
oding and promoter region is polymorphic, that this
equence variation affects how much blood CRP is made,
nd that this in turn affects CRP’s association to cardiovas-
Figure 2 The CRP Gene Is Located on Chromosome 1
The gene per se is comprised of 2 exons (red boxes) separated by a single
intron encoding a dinucleotide (gt) repeat. Exon 1 encodes an 18 amino acid
leader peptide (green box) and the first 2 amino acids of the mature protein.
The cross-hatched box demarcates the position of a reported alternative tran-
script. CRP  C-reactive protein; UTR  untranslated regions (yellow boxes).ular disease.
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September 18, 2007:1115–22 CRP Gene Polymorphismshe CRP Gene Is Polymorphic
ankow et al. (37) estimated that the interindividual varia-
ion in blood CRP level is 35% to 40% heritable. This has
ince been confirmed in twin studies (38–40). For example,
acGregor et al. (39) compared monozygotic versus dizy-
otic twin pairs and found that, although CRP was associ-
ted with body mass index, smoking status, and hormone
eplacement therapy, there was a greater correlation of CRP
evel among monozygotic than dizygotic twins, with an
stimated heritability of 52%. Similarly, Retterstol et al. (40)
ound in monozygotic twins the within-pair correlation
oefficient for CRP level was 0.40. Soon after it was
stablished that differences in CRP level associate with
enetic differences, efforts were made to identify different
RP gene polymorphisms to determine whether they di-
ectly affect the protein’s blood level. We have already
entioned that soon after the gene was sequenced, a
olymorphism in the length of the GT repeat in the CRP
ntron was identified (23,41). Some time later, Cao and
egele reported (42) the first coding region variation, i.e., a
ingle nucleotide polymorphism (SNP) in exon II of CRP.
hat SNP, 1059 G/C (rs1800947) (Table 1),2 is silent at
he amino acid level (CTG¡CTC, Leu¡Leu), and the
arer C allele was reportedly found in Caucasians but not
nuits (43). Pronounced ethnic and race effects are now
nown to be a general characteristic of the distribution of
RP gene polymorphs. Indeed, a recent systematic re-
equencing of the CRP gene revealed as many as 40 SNPs
orming as many as 29 different haplotypes, with by far the
ighest nucleotide diversity observed in African Americans
44). It is indisputable that the CRP gene is polymorphic.
Throughout the text, SNPs are identified using the terminology most commonly
NP in the CRP Gene
Table 1 SNP in the CRP Gene
Gene Region
SNP Position Commonly
Reported in the Literature NCBI refSNP ID
Promoter 757 rs3093059
717 rs2794521
409 rs3093062
390 rs3091244
Intron 29 rs1417938
Exon 2 1059 rs1800947
3= untranslated 219 rs3093066
1444 rs1130864
3= flanking 1846 rs1205
2911 rs3093068
Alleles are reported in order frommost frequent to least frequent as listed on the National Center
llele designationsmay differ from those commonly reported in the literature. †References to article
o C-reactive protein (CRP) blood level or disease status.
refSNP  reference single nucleotide polymorphism.C
sed in the literature. Wherever possible each is also cross-referenced to the NCBI
atabase using the reference (ref)SNP ID number or ‘rs’ number.RP Gene Polymorphisms Associate
ith Differences in CRP Blood Levels
urs was the first group to report an association between
RP gene polymorphism and baseline blood CRP (45). We
xamined the relationship between GT repeat alleles and
lood protein levels in patients with systemic lupus ery-
hematosus (SLE) versus healthy control patients and
herein identified 13 alleles ranging in length from 9 to 25
epeats (GT9 to GT25). Two of these, GT16 and GT21,
ccounted for more than 75% of all the alleles found. The
tatistical relationship between CRP genotype and CRP
lood level was best described by a sine-wave model having
periodicity of 5 GT repeats, with the GT16 and GT21
ariants associated with lowest CRP levels (Fig. 3). No
articular GT allele was associated with SLE (45).
Soon after our study was published, Brull et al. (46)
eported their own findings. They measured blood CRP in
ealthy men before and after 48 h of endurance exercise, and
n patients before and after coronary artery bypass graft
CABG) surgery and screened each of their respective CRP
enes. Two new polymorphisms were identified; a
717G/A SNP (rs2794521) in the CRP promoter and a
1444C/T SNP (rs1130864) in the 3= untranslated region.
he former did not associate with CRP, but 1444TT
omozygotes had significantly higher CRP at baseline, after
xercise training, and after CABG. The1444C/T SNP by
tself accounted for 3.7% of the total variance in baseline
lood CRP. Later the same group reported that CRP was
igher in periodontal patients carrying the 1444T versus
he C allele (47), and another group showed that healthy
oung men with the 1444TT genotype had 64% higher
lood CRP than those with the 1444CC genotype (48).
Many other CRP polymorphisms with association to
lood CRP level have since been reported. Thus, Obisesan
t al. (49) identified association between a 717A/G SNP
nd CRP levels before and after exercise training: blood
lative Allele
requency*
Nucleotide Associated
With Higher
CRP Blood Level Association Studies†
TC T (47,58,60,72)
TC T (46,49,52,57,58,66,67)
GA G (51)
CTA T (16,51,52,55,67,68,70,71)
AT A (49,50,60,67,72)
GC G (50,52,60–63,65,67,71,72)
CA C (49)
CT T (46–48,52,67,69,71)
CT C (65–67,69,72)
CG G (69)
echnology Information (NCBI) website. Depending on the deoxyribonucleic acid strand sequenced,
ssed in the text that studied the association of the indicated single nucleotide polymorphism (SNP)Re
F
for Biot
s discuRP was higher in 717AA homozygotes. A similar
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CRP Gene Polymorphisms September 18, 2007:1115–22orrelation was reported for a 219G/A SNP (rs3093066)
n the 3= untranslated region: GG homozygotes had higher
RP levels at baseline and after exercise (49). Impressively,
n a multivariate analysis, the 717A/G and 219G/A
NPs together accounted for almost 9% of the total varia-
ion in CRP blood level (49). Finally, a 29A/T SNP
rs1417938) was found to be significantly associated with
aseline CRP level: individuals with the A allele had higher
lood CRP, a relationship that persisted even after control-
ing for clinical characteristics (50). It is now clear that
olymorphisms in the CRP gene associate with differences
n CRP blood level.
ome CRP Gene Polymorphisms Are Functional
one of the polymorphisms so far discussed has been shown
o be functional, that is, to directly contribute to differences
n baseline CRP blood level among individuals. Few studies
ave actually pursued this question, and in the absence of
vidence, the common assumption made is that CRP
olymorphisms alter the structure of neighboring deoxyri-
onucleic acid and thus impede or bolster its translation to
essenger ribonucleic acid, or that known polymorphisms
re in linkage disequilibrium with yet-to-be identified
unctional polymorphisms. To investigate this issue, we
equenced the CRP promoter in 287 healthy individuals
nd identified 2 SNPs, a biallelic one at nucleotide
409G/A (rs3093062) and a triallelic one at 390C/T/A
rs3091244) (51). Blood CRP was lowest in people with the
409AA genotype, intermediate in 409GA, and highest
Figure 3 Association Between Baseline CRP and
the GT Repeat Polymorphism in the CRP Gene
Each circle and whisker is the mean  SEM for baseline (age-adjusted) CRP
obtained from the indicated number of individuals. The correlation coefficient
(r ) for the sine-wave regressions is given. The arrows point to the common
GT16 and GT21 variants having the lowest (approximately equal) CRP levels.
CRP  C-reactive protein.n 409GG, and there was a tendency toward high CRPalues in individuals carrying 390TT. Both SNPs reside
ithin E-box elements we named E-box 1 and E-box 2,
espectively. Using electrophoretic mobility shift assays, we
roved that both E-boxes are functional and that transcrip-
ion factors are capable of binding E-box 1. Importantly, the
NP in E-box 1 affects its ability to interact with transcrip-
ion factors. We also showed that individuals with a
409G/390T haplotype (the only haplotype found that
ncoded a high transcription factor binding version of
-box 1 and a transcription factor binding version of E-box
) had highest blood CRP, whereas individuals with
409A/390T (weak transcription factor binding versions
f both E-boxes) had the lowest (Fig. 4A). Individuals with
ither of the 2 remaining haplotypes had intermediate CRP
evels. Finally, using CRP promoter-firefly luciferase report-
rs, we confirmed that transcription at baseline and in
esponse to IL-6 was different for the different E-box
aplotypes (Fig. 4B). Impressively, carriers of the 409G/
390T haplotype who never smoked still had higher CRP
evels than 409G/390C carriers who currently did (51).
Kovacs et al. (52) also identified and studied the triallelic
390C/T/A SNP. They examined the correlation between
Figure 4 Association of CRP Promoter
Haplotype With Baseline CRP
Baseline C-reactive protein (CRP) concentration for the indicated number of
individuals having the various haplotypes (A) and the corresponding relative
luciferase light units (the ratio of firefly vs. Renilla luciferase activity) (B) is
reported as the mean  SEM (bars and whiskers). The numbers above the
bars give the fold-increase in promoter activity relative to the steady state.
IL  interleukin. Modified with permission from Szalai et al. (51).
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September 18, 2007:1115–22 CRP Gene Polymorphismshis SNP, a biallelic one at717A/G, the1059G/C SNP
n exon 2, and the 1444C/T SNP in the 3= flanking
egion. That study confirmed that the triallelic SNP corre-
ated with baseline CRP. In the large Framingham Heart
tudy (16), 9 of 13 CRP SNPs were found to be associated
ith blood CRP after adjustment for clinical covariates. Of
hese 9, only the triallelic SNP remained associated with
lood CRP after accounting for correlation among SNPs.
inally, because CRP level after an acute coronary syndrome
s predictive of recurrent events (53,54), Danik et al. (55)
valuated patients with acute coronary syndrome and found
hat the highest CRP blood level was associated with a
757T/C SNP (rs3093059) and again with the 390C/
/A SNP. The evidence from our initial study (51) and
ndependent additional studies thus points to at least 1 CRP
ene polymorphism that might truly be functional: 390C/
/A.
RP Gene Polymorphism
ssociates With Disease Status
ome of the most compelling reports of a strong association
etween CRP polymorphism and disease status did not
nclude measurement of blood CRP level as a variable. For
xample, Roy et al. (56) linked one poly(GT) allele (likely
T16) (Fig. 3) to increased susceptibility to infection with
treptococcus pneumonia, and Wolford et al. (57) found that
717TT was associated with an increased prevalence of
ype 2 diabetes mellitus. More recently, it was reported (58)
hat having the C allele at the 717T/C locus was signif-
cantly associated with training-induced improvements in
he insulin-sensitivity index.
Not all such studies revealed a gene–disease association.
hus, although baseline CRP is a good predictor of reste-
osis (59), investigation of the 1059G/C and 29T/A
NPs found no association with restenosis risk after angio-
lasty (60). These data consistently point toward an asso-
iation of CRP polymorphisms with blood CRP levels. The
trength and direction of this association appear to depend
n the type of disease, however, and the polymorphisms
ay or may not associate with disease risk.
he Big Question:
oes CRP Gene Polymorphism Alter
RP Blood Levels and Thus Disease Status?
ee et al. (61) examined the relationship of 1059G/C
ith blood CRP and risk of arterial thrombosis. In a large
ohort of healthy American men (726 case-control pairs),
2% were found to carry the C allele, and those turned out
o have lower median CRP values compared with indivi-
uals having the GG genotype. No correlation with arterial
hrombosis was found (61). Likewise, in the British
omen’s Heart and Health Study (62), carriers of1059C
ad lower blood CRP, but this did not affect blood pressure,
ulse pressure, or hypertension. In contrast, Balistreri et al.
63) found that CRP blood level was higher in subjects with Che C allele, and there was a higher frequency of1059C in
atients with a history of acute myocardial infarction com-
ared with healthy control patients. In a nested-case control
tudy of SLE (64), certain alleles of the intronic GT repeat
ere found to be associated with vascular events (myocardial
nfarction, stroke, peripheral arterial thrombosis, CABG,
ngina or claudication). Systemic lupus erythematosus pa-
ients with these vascular events were more likely than SLE
atients without them to have blood CRP in the highest
uintile of measured values, and these patients had a higher
revalence of the GT20 variant (64). In another study of
LE patients, Russell et al. (65) directly sequenced the CRP
ene in British families and found a correlation between
aseline blood CRP, the 1059G/C SNP, and a
1846G/A SNP (rs1205) in the 3= flanking region. The
atter was associated with SLE and the presence of anti-
uclear antibodies.
Other efforts to associate CRP gene polymorphism with
lood CRP level and disease status are noteworthy. For
xample, in Han Chinese subjects, although neither
717A/G nor 1846 A/G was found to correlate with
lood CRP, the frequency of the 717A allele was signif-
cantly higher among patients with coronary heart disease
han control patients. Impressively, in that study, individu-
ls carrying the A allele had an odds ratio for coronary heart
isease of 6.8 compared with those not carrying that allele
66). This finding has since been confirmed, as the same
NP was found to correlate with occurrence of myocardial
nfarction or thromboembolic stroke in the Physician’s
ealth Study (67). In a very recent and thorough examina-
ion of 7,159 individuals from the Third National Health
nd Nutrition Examination Survey, several CRP SNPs were
ound to be associated with CRP levels, but only the
unctional390C/T/A SNP was linked to both CRP levels
nd to increased prevalence of coronary heart disease (68).
ne interpretation of the findings of these studies, which
ere performed independently using diverse and unrelated
opulations, is that there are some CRP sequence polymor-
hisms that influence expression of the protein that might
lso affect cardiovascular well being.
All of the known CRP gene SNPs are in high-linkage
isequilibrium, so tag SNPs have been used to define
xtended CRP haplotypes. Using this approach, Kardys
t al. (69) found that although CRP blood level was
ssociated with incident coronary heart disease and varied
ith CRP haplotype, the different CRP haplotypes them-
elves were not associated with coronary heart disease. In
nother tag SNP investigation of subjects from the NHLBI
amily Heart Study, a trend toward a significant association
f CRP haplotypes with blood CRP was reported. In this
ase, the 757T/C and 390C/T/A SNPs showed the
trongest association. Again, however, none of the CRP
aplotypes or tag SNPs showed an association with intima-
edia thickness as measured by ultrasound (70). Another
tudy examining the correlation of various CRP SNPs to
RP blood level and arterial pulse wave velocity (71) found
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CRP Gene Polymorphisms September 18, 2007:1115–22tatistically significant association between CRP levels and
390C/T/A and 1444C/T, and there was association
f 1059G/C with pulse-wave velocity. Finally, in the
ardiovascular Health Study, 1846C/T, 29A/T,
1059G/C, and 757T/C were variably associated with
lood CRP. Not surprisingly, given that the distribution of
RP alleles differed among the races, the disease risk also
iffered among the races. Thus, in Caucasians 29A/T was
ssociated with increased risk of stroke and cardiovascular
ortality and 1059G/C and 1846C/T were associated
ith cardiovascular mortality, whereas in African Ameri-
ans 757T/C was associated with myocardial infarctions
72). At least some of the large-scale investigations using tag
NP approaches have provided some evidence that se-
uence differences in the CRP gene alter both CRP blood
evels and disease risk.
ummary
e have attempted here to bring together for comparison
nd contrast all of the published reports showing (or not
howing) that CRP gene polymorphisms associate with
RP blood levels or/and that CRP gene polymorphisms
ssociate with cardiovascular disease risk. Some noteworthy
atterns emerged. There is now ample direct evidence that
ome CRP gene polymorphisms affect the amount of CRP
roduced and indirect evidence that this in turn might have
n impact on vascular disease. In the CRP gene, intron
ariations in the GT repeat have been linked to changes in
lood CRP and the risk of vascular events, and the29A/T
NP was linked to blood CRP level but not to restenosis. In
xon II, the often-studied1059G/C SNP has been shown
o correlate well with blood CRP and in at least 1 study to
ssociate with pulse-wave velocity. It does not correlate,
owever, with arterial thrombosis, blood pressure, or reste-
osis. In the promoter region, the 390C/T/A triallelic
NP, the only functional CRP polymorphism so far de-
cribed, has been shown to correlate with blood CRP and
ecently has been directly linked to risk of cardiovascular
isease. The other SNPs in the promoter region have
ariable association with CRP level but good correlation
ith cardiac disease, diabetes mellitus, and insulin resis-
ance. In the 3= untranslated and 3= flanking regions there
re other SNPs that also correlate with blood CRP, but
one that associate with cardiovascular disease (although
1846C/T does associate with SLE). Importantly, nearly
0% of the total variation in CRP blood level can be
ccounted for by the CRP gene SNPs. This is remarkable
iven that CRP blood level is as much as 40% heritable. The
act that most studies have not been able to link CRP
olymorphisms to events is not that surprising, despite their
lear relationship to blood CRP level and of the latter to
ard clinical end points. Given the modest proportion of
ariation in blood CRP level that CRP polymorphisms
xplain, it would take a very large study (several orders of
agnitude larger than those so far undertaken) to see airect relationship between a particular SNP or CRP
aplotype and actual clinical events.
Coronary artery disease is considered by many to be a
isease of inflammation (73), and blood CRP has been
hown to be a powerful predictor of cardiovascular events
74,75). The effects of lifestyle and trans-acting factors not
ithstanding, it is now increasingly apparent that certain
ubtle variations in the CRP gene sequence predictably and
trongly influence blood CRP level. Furthermore, some of
hese variations map to cis-acting elements that have already
een associated with clinical correlates of cardiovascular
isease; notable in this respect is the triallelic SNP at
osition 390. New CRP SNPs and novel gene-protein-
isease associations will likely be reported at an increasing
ace, so the exact contribution of CRP gene polymorphisms
o the protein’s level and to disease status will continue to
efine itself. However, reports that individual SNPs in CRP
ight explain up to 10% of the variance in blood CRP level,
nd that the heritability of blood CRP is 30% to 40%,
uggest that identifying an individual’s CRP SNPs might
ne day be a practical and useful clinical approach for
rediction of cardiovascular event risk or for selecting
atients for treatment with CRP targeting drugs. Of course,
oving CRP genotyping to the clinical arena depends
ntirely on obtaining proof that CRP participates in disease
rocesses in humans, and that proof is still not available. If
ltimately CRP is found to not contribute to cardiovascular
iology, its utility as a marker of inflammation will not be
iminished. Ongoing and future studies will no doubt settle
he issue, but until then, there will always be critics and
upporters of the position that CRP blood levels and CRP
ene polymorphisms really matter.
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